Novartis announces the company’s financial results for the second quarter and first half of 2025.Novartis announces the company’s financial results for the second quarter and first half of 2025.
Showing 97 results
-
Eucreas®
( vildagliptin, metformin )Cardiovascular, Renal and Metabolism -
Exelon®
( rivastigmine )Neuroscience -
Exforge HCT®
( valsartan, amlodipine besylate, hydrochlorothiazide )Cardiovascular, Renal and Metabolism -
Exforge®
( valsartan, amlodipine besylate )Cardiovascular, Renal and Metabolism -
Exjade®
( deferasirox )Oncology -
Extavia®
( interferon beta-1b )Neuroscience -
Fabhalta®
( iptacopan ) -
Femara®
( letrozole )Oncology -
Galvus®
( vildagliptin )Cardiovascular, Renal and Metabolism -
Gilenya®
( fingolimod )Neuroscience